Overview: What is CMT? - Michael Shy, MD

Voice of the Patient - CMT Patient-Focused Drug Development Meeting
8:55am: Michael Shy, MD
The Hereditary Neuropathy Foundation will be hosting two ground-breaking patient-centered meetings to capture the “Voice of the Patient” so we can improve and implement protocols, treatments and the development of new therapeutics to meet our Charcot-Marie-Tooth (CMT) patients’ needs.
If you are a health care provider, researcher or industry stakeholder with an interest in improving outcomes for CMT patients, this important two day event should not be missed.
Day 1: Friday, September 28th, 2018: Externally-led Patient-Focused Drug Development (PFDD) Meeting:
The PFDD meeting is an opportunity for patients and families to inform the FDA, drug developers and other key stakeholders, on the true burdens of living with CMT and how patients view the benefits and risks of treatments for CMT.
This groundbreaking meeting will include facilitated panel discussions designed to provide the FDA with perspectives from people with hereditary neuropathies, advocates and caregivers. The day will focus primarily on a range of patient viewpoints on CMT, covering the symptoms and impacts to daily life that are most important to patients and patients’ perspectives on existing and future treatments.
For more about the Externally-led Patient-Focused Drug Development (PFDD) Meeting, read more at the link below.
www.hnf-cure.o....
To view the full agenda, visit:
www.hnf-cure.o....